VIVES Partners is a venture capital fund initiated by UCLouvain in 2004, dedicated to supporting early-stage science-based and technology-driven start-ups with positive societal impact, primarily in life sciences, AgTech, and hard engineering.
50% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 3 prior). Their most common stage is series-a (50% of deals). Average disclosed round size is $78.0M (across 6 rounds with reported amounts).
Portfolio
10
Fund Size
$80.5M
Top Stage
Series A
Last 12 Mo
2
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
14 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 e-Peas | Seed | $22M | Jul 2026 |
 NUCLIDIUM AG | Unknown | — | May 2026 |
 Generare | Series A | — | Jan 2026 |
| NUCLIDIUM AG | Series B | $79M | Jul 2025 |
| NUCLIDIUM AG | Series B | — | Jan 2025 |
| BBiocSol | Seed | — | Nov 2024 |
 ATB Therapeutics | Series A | — | Nov 2024 |
| e-Peas | Series A | $8M | Jan 2020 |
| SSyndesi Therapeutics | Series A | — | Jan 2018 |
| PPromethera Biosciences | Series A | — | Oct 2009 |
| BBionyra | Series A | $165M | — |
 Bionyra Pharma | Series A | $165M | — |
 Dreem | Unknown | $29M | — |
| Generare | Seed | — | — |
Top Co-Investors
Noshaq3 shared
Angelini Ventures3 shared
Eurazeo3 shared
Wellington Management3 shared
Bayern Kapital3 shared
DeepTech & Climate Fonds (DTCF)3 shared
Neva SGR3 shared
Kurma Partners3 shared
NRW.BANK3 shared
Airbus Ventures2 shared
SFPIM2 shared
KBC Focus Fund2 shared
Wallonie Entreprendre2 shared
LeanSquare2 shared
Sanofi Ventures2 shared
Apollo Health Ventures2 shared
Jeito Capital2 shared
Sixty Degree Capital2 shared
Arkin Bio Ventures2 shared
Sofinnova Partners2 shared
Last updated: 20 October 2026